Showing results (241-250 of 498) with videos related to

Sort By:
Pageof 50
Leukemia|May 12, 2018
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN studyStephan Stilgenbauer, Veronique Leblond, Robin Foà, et al.
Leukemia & Lymphoma|February 23, 2011
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational studyCorinne Haioun, Antonio Salar, Ruth Pettengell, et al.
Leukemia Research|March 6, 2012
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practiceAntonio Salar, Corinne Haioun, Francesca G Rossi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 22, 2011
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaRuth Pettengell, Hans E Johnsen, Hans E Johnson, et al.
Hemasphere|August 28, 2024
Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximabArnon P Kater, Barbara F Eichhorst, Carolyn J Owen, et al.
Haematologica|January 4, 2011
White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemiaIlaria Del Giudice, Francesca Romana Mauro, Maria Stefania De Propris, et al.
Blood|November 2, 2006
MEK blockade converts AML differentiating response to retinoids into extensive apoptosisMichele Milella, Marina Konopleva, Cristina M Precupanu, et al.
Blood|February 7, 2014
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemiaDavide Rossi, Hossein Khiabanian, Valeria Spina, et al.
Experimental Hematology|November 29, 2011
A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosisMaria Giulia Bacalini, Simona Tavolaro, Nadia Peragine, et al.
Annals of Hematology|March 7, 2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patientsEmilia Scalzulli, Giovanni Caocci, Fabio Efficace, et al.
Pageof 50